25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

NVZMY (Novozymes AS) Stock Analysis
Buy, Hold or Sell?

Let's analyze Novozymes AS together

I guess you are interested in Novozymes AS. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • 📊 Fundamental Analysis (FA) – Novozymes AS’s Financial Insights
  • 📈 Technical Analysis (TA) – Novozymes AS’s Price Targets

I'm going to help you getting a better view of Novozymes AS. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Novozymes AS

I send you an email if I find something interesting about Novozymes AS.

1. Quick Overview

1.1. Quick analysis of Novozymes AS (30 sec.)










1.2. What can you expect buying and holding a share of Novozymes AS? (30 sec.)

How much money do you get?

How much money do you get?
$2.57
When do you have the money?
1 year
How often do you get paid?
100.0%

What is your share worth?

Current worth
$28.71
Expected worth in 1 year
$-19.86
How sure are you?
90.0%

+ What do you gain per year?

Total Gains per Share
$-46.01
Return On Investment
-64.0%

For what price can you sell your share?

Current Price per Share
$71.84
Expected price per share
$62.86 - $75.99
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Novozymes AS (5 min.)




Live pricePrice per Share (EOD)
$71.84
Intrinsic Value Per Share
$-51.50 - $12.09
Total Value Per Share
$-22.78 - $40.81

2.2. Growth of Novozymes AS (5 min.)




Is Novozymes AS growing?

Current yearPrevious yearGrowGrow %
How rich?$13.1b$16.8b-$3.7b-28.4%

How much money is Novozymes AS making?

Current yearPrevious yearGrowGrow %
Making money$358.5m$3.5b-$3.1b-888.9%
Net Profit Margin8.0%16.9%--

How much money comes from the company's main activities?

2.3. Financial Health of Novozymes AS (5 min.)




2.4. Comparing to competitors in the Specialty Chemicals industry (5 min.)




  Industry Rankings (Specialty Chemicals)  


Richest
#8 / 512

Most Revenue
#20 / 512

Most Profit
#15 / 512

Most Efficient
#134 / 512
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Novozymes AS?

Welcome investor! Novozymes AS's management wants to use your money to grow the business. In return you get a share of Novozymes AS.

First you should know what it really means to hold a share of Novozymes AS. And how you can make/lose money.

Speculation

The Price per Share of Novozymes AS is $71.84. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Novozymes AS.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Novozymes AS, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $28.71. Based on the TTM, the Book Value Change Per Share is $-12.14 per quarter. Based on the YOY, the Book Value Change Per Share is $0.35 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.64 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Novozymes AS.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps0.791.1%0.791.1%8.6112.0%6.629.2%7.3710.3%7.3810.3%
Usd Book Value Change Per Share-12.14-16.9%-12.14-16.9%0.350.5%-2.01-2.8%-0.79-1.1%-0.34-0.5%
Usd Dividend Per Share0.640.9%0.640.9%8.1311.3%4.376.1%4.306.0%3.845.3%
Usd Total Gains Per Share-11.50-16.0%-11.50-16.0%8.4811.8%2.363.3%3.514.9%3.504.9%
Usd Price Per Share56.54-56.54-54.91-53.97-60.42-53.50-
Price to Earnings Ratio71.97-71.97-6.38-27.72-19.91-16.11-
Price-to-Total Gains Ratio-4.92--4.92-6.47-2.19-6.93-10.84-
Price to Book Ratio1.97-1.97-1.34-1.52-1.75-1.59-
Price-to-Total Gains Ratio-4.92--4.92-6.47-2.19-6.93-10.84-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share71.84
Number of shares13
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.644.30
Usd Book Value Change Per Share-12.14-0.79
Usd Total Gains Per Share-11.503.51
Gains per Quarter (13 shares)-149.5345.60
Gains per Year (13 shares)-598.11182.41
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
133-631-608224-41172
267-1263-1206447-83354
3100-1894-1804671-124536
4133-2526-2402895-165718
5167-3157-30001119-206900
6200-3789-35981342-2481082
7234-4420-41961566-2891264
8267-5052-47941790-3301446
9300-5683-53922013-3721628
10334-6315-59902237-4131810

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%10.00.00.0100.0%23.00.00.0100.0%
Book Value Change Per Share0.01.00.00.0%2.01.00.066.7%3.02.00.060.0%7.03.00.070.0%16.07.00.069.6%
Dividend per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%10.00.00.0100.0%23.00.00.0100.0%
Total Gains per Share0.01.00.00.0%2.01.00.066.7%4.01.00.080.0%9.01.00.090.0%20.03.00.087.0%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Novozymes AS compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share---12.144-12.1440%0.350-3568%-2.012-83%-0.794-93%-0.340-97%
Book Value Per Share--28.71328.7130%40.857-30%36.692-22%35.367-19%34.060-16%
Current Ratio--1.7271.7270%1.303+33%1.452+19%1.479+17%1.512+14%
Debt To Asset Ratio--0.2650.2650%0.495-47%0.417-37%0.442-40%0.417-37%
Debt To Equity Ratio--0.3600.3600%1.004-64%0.786-54%0.849-58%0.751-52%
Dividend Per Share--0.6420.6420%8.131-92%4.371-85%4.302-85%3.840-83%
Enterprise Value--21425458429.60921425458429.6090%7459589000.000+187%11617961276.536+84%13948507925.922+54%12621374682.961+70%
Eps--0.7860.7860%8.609-91%6.620-88%7.372-89%7.376-89%
Ev To Ebitda Ratio--27.72627.7260%1.163+2284%9.907+180%7.123+289%4.525+513%
Ev To Sales Ratio--4.7664.7660%0.355+1241%1.804+164%1.491+220%1.082+340%
Free Cash Flow Per Share--1.6961.6960%5.967-72%3.613-53%5.719-70%6.216-73%
Free Cash Flow To Equity Per Share---0.111-0.1110%0.589-119%0.032-442%1.350-108%0.105-205%
Gross Profit Margin---0.802-0.8020%0.218-468%-0.067-92%0.125-743%0.301-366%
Intrinsic Value_10Y_max--12.093----------
Intrinsic Value_10Y_min---51.497----------
Intrinsic Value_1Y_max--5.149----------
Intrinsic Value_1Y_min--1.416----------
Intrinsic Value_3Y_max--12.469----------
Intrinsic Value_3Y_min---1.417----------
Intrinsic Value_5Y_max--16.173----------
Intrinsic Value_5Y_min---10.442----------
Market Cap29589459200.000+13%25805822989.60925805822989.6090%22614271400.000+14%23067853063.203+12%25389003277.922+2%22287186838.961+16%
Net Profit Margin--0.0800.0800%0.169-53%0.153-48%0.174-54%0.195-59%
Operating Margin----0%0.228-100%0.164-100%0.201-100%0.239-100%
Operating Ratio--0.8280.8280%0.778+6%0.782+6%0.766+8%0.746+11%
Pb Ratio2.502+21%1.9691.9690%1.344+47%1.520+30%1.747+13%1.586+24%
Pe Ratio91.441+21%71.96671.9660%6.378+1028%27.722+160%19.908+261%16.106+347%
Price Per Share71.840+21%56.54056.5400%54.905+3%53.968+5%60.419-6%53.499+6%
Price To Free Cash Flow Ratio42.361+21%33.33933.3390%9.201+262%19.474+71%14.928+123%10.965+204%
Price To Total Gains Ratio-6.246-27%-4.916-4.9160%6.474-176%2.185-325%6.931-171%10.843-145%
Quick Ratio--1.0041.0040%0.679+48%0.791+27%0.810+24%0.825+22%
Return On Assets--0.0200.0200%0.107-81%0.086-77%0.105-81%0.133-85%
Return On Equity--0.0270.0270%0.216-87%0.170-84%0.205-87%0.237-88%
Total Gains Per Share---11.502-11.5020%8.481-236%2.359-588%3.508-428%3.500-429%
Usd Book Value--13104977600.00013104977600.0000%16827982600.000-22%15538904333.333-16%14822836600.000-12%14156565280.000-7%
Usd Book Value Change Per Share---12.144-12.1440%0.350-3568%-2.012-83%-0.794-93%-0.340-97%
Usd Book Value Per Share--28.71328.7130%40.857-30%36.692-22%35.367-19%34.060-16%
Usd Dividend Per Share--0.6420.6420%8.131-92%4.371-85%4.302-85%3.840-83%
Usd Enterprise Value--21425458429.60921425458429.6090%7459589000.000+187%11617961276.536+84%13948507925.922+54%12621374682.961+70%
Usd Eps--0.7860.7860%8.609-91%6.620-88%7.372-89%7.376-89%
Usd Free Cash Flow--774033260.000774033260.0000%2457769600.000-69%1513474820.000-49%2370786132.000-67%2567771206.000-70%
Usd Free Cash Flow Per Share--1.6961.6960%5.967-72%3.613-53%5.719-70%6.216-73%
Usd Free Cash Flow To Equity Per Share---0.111-0.1110%0.589-119%0.032-442%1.350-108%0.105-205%
Usd Market Cap29589459200.000+13%25805822989.60925805822989.6090%22614271400.000+14%23067853063.203+12%25389003277.922+2%22287186838.961+16%
Usd Price Per Share71.840+21%56.54056.5400%54.905+3%53.968+5%60.419-6%53.499+6%
Usd Profit--358581080.000358581080.0000%3545942400.000-90%2738333693.333-87%3043319136.000-88%3324180288.000-89%
Usd Revenue--4495162100.0004495162100.0000%20988367400.000-79%15355392433.333-71%16005638220.000-72%16379756250.000-73%
Usd Total Gains Per Share---11.502-11.5020%8.481-236%2.359-588%3.508-428%3.500-429%
 EOD+3 -5MRQTTM+0 -0YOY+11 -293Y+11 -295Y+11 -2910Y+11 -29

3.3 Fundamental Score

Let's check the fundamental score of Novozymes AS based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1591.441
Price to Book Ratio (EOD)Between0-12.502
Net Profit Margin (MRQ)Greater than00.080
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than11.004
Current Ratio (MRQ)Greater than11.727
Debt to Asset Ratio (MRQ)Less than10.265
Debt to Equity Ratio (MRQ)Less than10.360
Return on Equity (MRQ)Greater than0.150.027
Return on Assets (MRQ)Greater than0.050.020
Total5/10 (50.0%)

3.4 Technical Score

Let's check the technical score of Novozymes AS based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5051.009
Ma 20Greater thanMa 5072.814
Ma 50Greater thanMa 10070.296
Ma 100Greater thanMa 20064.734
OpenGreater thanClose71.290
Total4/5 (80.0%)

4. In-depth Analysis

4.1 About Novozymes AS

Novozymes A/S produces and sells produces various industrial enzymes, functional proteins, and microorganisms in Denmark, rest of Europe, North America, Asia Pacific, the Middle East, Africa, Latin America, and internationally. The company offers biosolutions for the food and beverage industry, such as dairy, baking, beverage, meat, plant-based, functional, and other foods, as well as protein solutions and early lie nutrition. It also offers industrial hygiene, drain openers, hard surface, medical cleaning, septic tanks, ware washing, and professional laundry services. In addition, the company provides dishwashing, softener, microbial and medical cleaning services. Further, it provides corn, cotton, forages, peanuts, pulses, soybeans, wheat, small grains, bioyield, and biocontrol solutions; warm water species, recirculating aquaculture system; animal health and nutrition solutions; fiber modification, bleach boosting, deposit control, and starch modification solutions. Additionally, the company provides carbon capture, leather and textiles solutions; enzyme solutions, including corn and wheat separation, liquefaction, saccharification, filtration, isomerization, maltose, and specialties solutions; warm water species and recirculating aquaculture system solutions; human health solutions, comprising brain, oral, protective and immune, and gastrointestinal health solutions; ethanol, biodiesel, renewable diesel, wastewater, and sewage, and renewable diesel solutions; agriculture and industry, biogas food waste, food waste, biocatalysis, cell culture, enzyme, and biogas solutions. Furthermore, it provides lipases, proteases, oxidoreductases, and carbohydrases. Novozymes A/S was founded in 1925 and is based in Bagsvaerd, Denmark.

Fundamental data was last updated by Penke on 2025-07-01 21:31:07.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is less efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is just able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is fair priced.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Novozymes AS earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Novozymes AS to the Specialty Chemicals industry mean.
  • A Net Profit Margin of 8.0% means that $0.08 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Novozymes AS:

  • The MRQ is 8.0%. The company is making a profit. +1
  • The TTM is 8.0%. The company is making a profit. +1
Trends
Current periodCompared to+/- 
MRQ8.0%TTM8.0%0.0%
TTM8.0%YOY16.9%-8.9%
TTM8.0%5Y17.4%-9.4%
5Y17.4%10Y19.5%-2.1%
Compared to industry (Specialty Chemicals)
PeriodCompanyIndustry (mean)+/- 
MRQ8.0%3.6%+4.4%
TTM8.0%3.4%+4.6%
YOY16.9%3.7%+13.2%
3Y15.3%3.9%+11.4%
5Y17.4%5.4%+12.0%
10Y19.5%5.6%+13.9%
4.3.1.2. Return on Assets

Shows how efficient Novozymes AS is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Novozymes AS to the Specialty Chemicals industry mean.
  • 2.0% Return on Assets means that Novozymes AS generated $0.02 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Novozymes AS:

  • The MRQ is 2.0%. Using its assets, the company is less efficient in making profit.
  • The TTM is 2.0%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ2.0%TTM2.0%0.0%
TTM2.0%YOY10.7%-8.6%
TTM2.0%5Y10.5%-8.4%
5Y10.5%10Y13.3%-2.9%
Compared to industry (Specialty Chemicals)
PeriodCompanyIndustry (mean)+/- 
MRQ2.0%0.9%+1.1%
TTM2.0%0.9%+1.1%
YOY10.7%0.9%+9.8%
3Y8.6%1.0%+7.6%
5Y10.5%1.3%+9.2%
10Y13.3%1.5%+11.8%
4.3.1.3. Return on Equity

Shows how efficient Novozymes AS is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Novozymes AS to the Specialty Chemicals industry mean.
  • 2.7% Return on Equity means Novozymes AS generated $0.03 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Novozymes AS:

  • The MRQ is 2.7%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 2.7%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ2.7%TTM2.7%0.0%
TTM2.7%YOY21.6%-18.9%
TTM2.7%5Y20.5%-17.8%
5Y20.5%10Y23.7%-3.1%
Compared to industry (Specialty Chemicals)
PeriodCompanyIndustry (mean)+/- 
MRQ2.7%1.6%+1.1%
TTM2.7%1.6%+1.1%
YOY21.6%1.8%+19.8%
3Y17.0%2.0%+15.0%
5Y20.5%2.4%+18.1%
10Y23.7%2.6%+21.1%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Novozymes AS.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Novozymes AS is operating .

  • Measures how much profit Novozymes AS makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Novozymes AS to the Specialty Chemicals industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Novozymes AS:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY22.8%-22.8%
TTM-5Y20.1%-20.1%
5Y20.1%10Y23.9%-3.8%
Compared to industry (Specialty Chemicals)
PeriodCompanyIndustry (mean)+/- 
MRQ-8.0%-8.0%
TTM-6.2%-6.2%
YOY22.8%4.3%+18.5%
3Y16.4%4.0%+12.4%
5Y20.1%6.7%+13.4%
10Y23.9%6.9%+17.0%
4.3.2.2. Operating Ratio

Measures how efficient Novozymes AS is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Specialty Chemicals industry mean).
  • An Operation Ratio of 0.83 means that the operating costs are $0.83 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Novozymes AS:

  • The MRQ is 0.828. The company is less efficient in keeping operating costs low.
  • The TTM is 0.828. The company is less efficient in keeping operating costs low.
Trends
Current periodCompared to+/- 
MRQ0.828TTM0.8280.000
TTM0.828YOY0.778+0.050
TTM0.8285Y0.766+0.062
5Y0.76610Y0.746+0.020
Compared to industry (Specialty Chemicals)
PeriodCompanyIndustry (mean)+/- 
MRQ0.8281.579-0.751
TTM0.8281.477-0.649
YOY0.7781.094-0.316
3Y0.7821.260-0.478
5Y0.7661.172-0.406
10Y0.7461.097-0.351
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Novozymes AS.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Novozymes AS is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Specialty Chemicals industry mean).
  • A Current Ratio of 1.73 means the company has $1.73 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Novozymes AS:

  • The MRQ is 1.727. The company is able to pay all its short-term debts. +1
  • The TTM is 1.727. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ1.727TTM1.7270.000
TTM1.727YOY1.303+0.424
TTM1.7275Y1.479+0.248
5Y1.47910Y1.512-0.033
Compared to industry (Specialty Chemicals)
PeriodCompanyIndustry (mean)+/- 
MRQ1.7271.835-0.108
TTM1.7271.850-0.123
YOY1.3031.902-0.599
3Y1.4521.914-0.462
5Y1.4791.941-0.462
10Y1.5121.907-0.395
4.4.3.2. Quick Ratio

Measures if Novozymes AS is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Novozymes AS to the Specialty Chemicals industry mean.
  • A Quick Ratio of 1.00 means the company can pay off $1.00 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Novozymes AS:

  • The MRQ is 1.004. The company is just able to pay all its short-term debts with the most liquid assets.
  • The TTM is 1.004. The company is just able to pay all its short-term debts with the most liquid assets.
Trends
Current periodCompared to+/- 
MRQ1.004TTM1.0040.000
TTM1.004YOY0.679+0.325
TTM1.0045Y0.810+0.194
5Y0.81010Y0.825-0.015
Compared to industry (Specialty Chemicals)
PeriodCompanyIndustry (mean)+/- 
MRQ1.0040.762+0.242
TTM1.0040.797+0.207
YOY0.6790.943-0.264
3Y0.7910.979-0.188
5Y0.8101.066-0.256
10Y0.8251.130-0.305
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Novozymes AS.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Novozymes AS assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Novozymes AS to Specialty Chemicals industry mean.
  • A Debt to Asset Ratio of 0.26 means that Novozymes AS assets are financed with 26.5% credit (debt) and the remaining percentage (100% - 26.5%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Novozymes AS:

  • The MRQ is 0.265. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.265. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.265TTM0.2650.000
TTM0.265YOY0.495-0.230
TTM0.2655Y0.442-0.177
5Y0.44210Y0.417+0.025
Compared to industry (Specialty Chemicals)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2650.432-0.167
TTM0.2650.430-0.165
YOY0.4950.428+0.067
3Y0.4170.428-0.011
5Y0.4420.421+0.021
10Y0.4170.433-0.016
4.5.4.2. Debt to Equity Ratio

Measures if Novozymes AS is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Novozymes AS to the Specialty Chemicals industry mean.
  • A Debt to Equity ratio of 36.0% means that company has $0.36 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Novozymes AS:

  • The MRQ is 0.360. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.360. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.360TTM0.3600.000
TTM0.360YOY1.004-0.645
TTM0.3605Y0.849-0.489
5Y0.84910Y0.751+0.099
Compared to industry (Specialty Chemicals)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3600.780-0.420
TTM0.3600.765-0.405
YOY1.0040.771+0.233
3Y0.7860.776+0.010
5Y0.8490.801+0.048
10Y0.7510.845-0.094
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Novozymes AS generates.

  • Above 15 is considered overpriced but always compare Novozymes AS to the Specialty Chemicals industry mean.
  • A PE ratio of 71.97 means the investor is paying $71.97 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Novozymes AS:

  • The EOD is 91.441. Based on the earnings, the company is expensive. -2
  • The MRQ is 71.966. Based on the earnings, the company is expensive. -2
  • The TTM is 71.966. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD91.441MRQ71.966+19.475
MRQ71.966TTM71.9660.000
TTM71.966YOY6.378+65.589
TTM71.9665Y19.908+52.058
5Y19.90810Y16.106+3.802
Compared to industry (Specialty Chemicals)
PeriodCompanyIndustry (mean)+/- 
EOD91.44118.184+73.257
MRQ71.96617.025+54.941
TTM71.96615.744+56.222
YOY6.37817.936-11.558
3Y27.72217.307+10.415
5Y19.90819.782+0.126
10Y16.10624.685-8.579
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Novozymes AS:

  • The EOD is 42.361. Based on how much money comes from the company's main activities, the company is fair priced.
  • The MRQ is 33.339. Based on how much money comes from the company's main activities, the company is fair priced.
  • The TTM is 33.339. Based on how much money comes from the company's main activities, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD42.361MRQ33.339+9.022
MRQ33.339TTM33.3390.000
TTM33.339YOY9.201+24.138
TTM33.3395Y14.928+18.412
5Y14.92810Y10.965+3.963
Compared to industry (Specialty Chemicals)
PeriodCompanyIndustry (mean)+/- 
EOD42.361-2.695+45.056
MRQ33.339-2.695+36.034
TTM33.3391.612+31.727
YOY9.2013.816+5.385
3Y19.4742.259+17.215
5Y14.9283.182+11.746
10Y10.9653.363+7.602
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Novozymes AS is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Specialty Chemicals industry mean).
  • A PB ratio of 1.97 means the investor is paying $1.97 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Novozymes AS:

  • The EOD is 2.502. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.969. Based on the equity, the company is underpriced. +1
  • The TTM is 1.969. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD2.502MRQ1.969+0.533
MRQ1.969TTM1.9690.000
TTM1.969YOY1.344+0.625
TTM1.9695Y1.747+0.222
5Y1.74710Y1.586+0.161
Compared to industry (Specialty Chemicals)
PeriodCompanyIndustry (mean)+/- 
EOD2.5021.663+0.839
MRQ1.9691.601+0.368
TTM1.9691.635+0.334
YOY1.3441.832-0.488
3Y1.5201.869-0.349
5Y1.7472.263-0.516
10Y1.5862.765-1.179
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2024-12-31. Currency in EUR. All numbers in thousands.

Summary
Total Assets15,195,600
Total Liabilities4,019,600
Total Stockholder Equity11,176,000
 As reported
Total Liabilities 4,019,600
Total Stockholder Equity+ 11,176,000
Total Assets = 15,195,600

Assets

Total Assets15,195,600
Total Current Assets1,879,400
Long-term Assets13,316,200
Total Current Assets
Cash And Cash Equivalents 280,000
Short-term Investments 4,000
Net Receivables 804,600
Inventory 720,600
Other Current Assets 70,200
Total Current Assets  (as reported)1,879,400
Total Current Assets  (calculated)1,879,400
+/-0
Long-term Assets
Property Plant Equipment 2,968,300
Goodwill 5,605,000
Intangible Assets 4,419,200
Long-term Assets Other 10,000
Long-term Assets  (as reported)13,316,200
Long-term Assets  (calculated)13,002,500
+/- 313,700

Liabilities & Shareholders' Equity

Total Current Liabilities1,088,300
Long-term Liabilities2,931,300
Total Stockholder Equity11,176,000
Total Current Liabilities
Short-term Debt 266,400
Short Long Term Debt 266,400
Accounts payable 423,100
Other Current Liabilities 337,900
Total Current Liabilities  (as reported)1,088,300
Total Current Liabilities  (calculated)1,293,800
+/- 205,500
Long-term Liabilities
Long term Debt 1,530,400
Long-term Liabilities  (as reported)2,931,300
Long-term Liabilities  (calculated)1,530,400
+/- 1,400,900
Total Stockholder Equity
Common Stock125,600
Retained Earnings 11,032,400
Other Stockholders Equity 18,000
Total Stockholder Equity (as reported)11,176,000
Total Stockholder Equity (calculated)11,176,000
+/-0
Other
Capital Stock125,600
Cash and Short Term Investments 284,000
Common Stock Shares Outstanding 456,418
Liabilities and Stockholders Equity 15,195,600
Net Debt 1,516,800
Net Invested Capital 12,972,800
Net Working Capital 791,100
Short Long Term Debt Total 1,796,800



6.2. Balance Sheets Structured

Currency in EUR. All numbers in thousands.

 Trend2024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-312008-12-312007-12-312006-12-312005-12-312004-12-312003-12-312002-12-31
> Total Assets 
8,350,000
7,633,000
7,134,000
7,309,000
7,965,000
8,871,000
9,925,000
10,890,000
12,593,000
13,842,000
15,113,000
16,506,000
18,426,000
17,791,000
18,659,000
18,373,000
19,697,000
20,437,000
20,510,000
24,767,000
27,983,000
28,391,000
15,195,600
15,195,60028,391,00027,983,00024,767,00020,510,00020,437,00019,697,00018,373,00018,659,00017,791,00018,426,00016,506,00015,113,00013,842,00012,593,00010,890,0009,925,0008,871,0007,965,0007,309,0007,134,0007,633,0008,350,000
   > Total Current Assets 
3,776,000
3,316,000
3,141,000
3,339,000
3,586,000
3,653,000
4,284,000
4,899,000
5,536,000
4,789,000
4,890,000
5,830,000
7,311,000
6,148,000
6,393,000
6,137,000
6,835,000
7,050,000
6,911,000
7,823,000
9,241,000
9,462,000
1,879,400
1,879,4009,462,0009,241,0007,823,0006,911,0007,050,0006,835,0006,137,0006,393,0006,148,0007,311,0005,830,0004,890,0004,789,0005,536,0004,899,0004,284,0003,653,0003,586,0003,339,0003,141,0003,316,0003,776,000
       Cash And Cash Equivalents 
832,000
571,000
531,000
454,000
497,000
460,000
997,000
1,284,000
1,465,000
667,000
535,000
1,003,000
2,535,000
839,000
812,000
632,000
723,000
711,000
1,181,000
963,000
1,041,000
1,116,000
280,000
280,0001,116,0001,041,000963,0001,181,000711,000723,000632,000812,000839,0002,535,0001,003,000535,000667,0001,465,0001,284,000997,000460,000497,000454,000531,000571,000832,000
       Short-term Investments 
166,000
115,000
93,000
151,000
177,000
0
0
0
178,000
48,000
45,000
87,000
17,000
20,000
4,000
16,000
14,000
15,000
119,000
75,000
80,000
40,000
4,000
4,00040,00080,00075,000119,00015,00014,00016,0004,00020,00017,00087,00045,00048,000178,000000177,000151,00093,000115,000166,000
       Net Receivables 
0
0
0
0
0
1,675,000
1,614,000
1,893,000
0
0
2,080,000
2,242,000
2,244,000
2,558,000
2,680,000
2,554,000
2,885,000
3,107,000
2,555,000
2,988,000
3,605,000
3,772,000
804,600
804,6003,772,0003,605,0002,988,0002,555,0003,107,0002,885,0002,554,0002,680,0002,558,0002,244,0002,242,0002,080,000001,893,0001,614,0001,675,00000000
       Inventory 
1,318,000
1,117,000
1,130,000
1,197,000
1,326,000
1,322,000
1,557,000
1,535,000
1,640,000
1,741,000
1,808,000
1,902,000
2,184,000
2,281,000
2,488,000
2,586,000
2,820,000
2,613,000
2,361,000
2,992,000
3,803,000
3,627,000
720,600
720,6003,627,0003,803,0002,992,0002,361,0002,613,0002,820,0002,586,0002,488,0002,281,0002,184,0001,902,0001,808,0001,741,0001,640,0001,535,0001,557,0001,322,0001,326,0001,197,0001,130,0001,117,0001,318,000
       Other Current Assets 
1,460,000
1,513,000
1,387,000
1,537,000
1,586,000
196,000
116,000
187,000
2,253,000
2,333,000
467,000
683,000
348,000
470,000
413,000
365,000
407,000
619,000
814,000
880,000
792,000
947,000
70,200
70,200947,000792,000880,000814,000619,000407,000365,000413,000470,000348,000683,000467,0002,333,0002,253,000187,000116,000196,0001,586,0001,537,0001,387,0001,513,0001,460,000
   > Long-term Assets 
4,574,000
4,317,000
3,993,000
3,970,000
4,379,000
5,218,000
5,641,000
5,991,000
7,057,000
9,053,000
10,223,000
10,676,000
11,115,000
11,643,000
12,266,000
12,236,000
12,862,000
13,387,000
13,599,000
16,944,000
18,742,000
18,929,000
13,316,200
13,316,20018,929,00018,742,00016,944,00013,599,00013,387,00012,862,00012,236,00012,266,00011,643,00011,115,00010,676,00010,223,0009,053,0007,057,0005,991,0005,641,0005,218,0004,379,0003,970,0003,993,0004,317,0004,574,000
       Property Plant Equipment 
3,985,000
3,783,000
3,522,000
3,477,000
3,553,000
3,842,000
4,319,000
4,804,000
5,866,000
6,557,000
7,084,000
7,135,000
7,498,000
8,162,000
8,641,000
8,926,000
9,698,000
10,212,000
9,612,000
10,185,000
12,074,000
12,325,000
2,968,300
2,968,30012,325,00012,074,00010,185,0009,612,00010,212,0009,698,0008,926,0008,641,0008,162,0007,498,0007,135,0007,084,0006,557,0005,866,0004,804,0004,319,0003,842,0003,553,0003,477,0003,522,0003,783,0003,985,000
       Goodwill 
117,000
125,000
95,000
120,000
216,000
500,000
415,000
0
0
0
811,000
1,022,000
1,113,000
1,140,000
1,159,000
1,108,000
1,086,000
965,000
1,098,000
2,020,000
2,007,000
1,975,000
5,605,000
5,605,0001,975,0002,007,0002,020,0001,098,000965,0001,086,0001,108,0001,159,0001,140,0001,113,0001,022,000811,000000415,000500,000216,000120,00095,000125,000117,000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
59,000
8,611
33,468
0
0
0
0
0
0
0
0
0
00000000033,4688,61159,00000000000000
       Intangible Assets 
435,000
409,000
376,000
311,000
553,000
821,000
764,000
1,124,000
1,070,000
2,221,000
1,861,000
1,842,000
1,841,000
1,536,000
1,578,000
1,324,000
1,044,000
961,000
1,456,000
3,004,000
2,691,000
343,444
4,419,200
4,419,200343,4442,691,0003,004,0001,456,000961,0001,044,0001,324,0001,578,0001,536,0001,841,0001,842,0001,861,0002,221,0001,070,0001,124,000764,000821,000553,000311,000376,000409,000435,000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
618,000
99,103
83,669
664,000
790,000
972,000
1,190,000
1,379,000
1,676,000
1,747,000
0
0
001,747,0001,676,0001,379,0001,190,000972,000790,000664,00083,66999,103618,00000000000000
> Total Liabilities 
4,102,000
3,458,000
3,242,000
3,515,000
4,572,000
5,204,000
5,449,000
5,039,000
4,757,000
5,018,000
5,545,000
5,440,000
7,146,000
6,198,000
6,914,000
7,106,000
8,259,000
8,957,000
9,266,000
12,561,000
13,755,000
14,040,000
4,019,600
4,019,60014,040,00013,755,00012,561,0009,266,0008,957,0008,259,0007,106,0006,914,0006,198,0007,146,0005,440,0005,545,0005,018,0004,757,0005,039,0005,449,0005,204,0004,572,0003,515,0003,242,0003,458,0004,102,000
   > Total Current Liabilities 
1,160,000
1,449,000
1,223,000
1,442,000
1,938,000
2,394,000
2,886,000
2,521,000
2,508,000
2,357,000
2,620,000
2,599,000
3,941,000
3,300,000
3,562,000
4,577,000
5,525,000
4,735,000
4,161,000
5,673,000
6,963,000
7,262,000
1,088,300
1,088,3007,262,0006,963,0005,673,0004,161,0004,735,0005,525,0004,577,0003,562,0003,300,0003,941,0002,599,0002,620,0002,357,0002,508,0002,521,0002,886,0002,394,0001,938,0001,442,0001,223,0001,449,0001,160,000
       Short-term Debt 
204,000
373,000
48,000
0
0
0
0
0
0
0
243,000
-264,000
-256,000
-295,000
-348,000
487,000
1,789,000
1,543,000
1,242,000
2,098,000
3,042,000
3,173,000
266,400
266,4003,173,0003,042,0002,098,0001,242,0001,543,0001,789,000487,000-348,000-295,000-256,000-264,000243,000000000048,000373,000204,000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
1,788,000
96,504
10,768
89,000
971,000
1,789,000
0
0
272,815
2,818,000
3,036,000
266,400
266,4003,036,0002,818,000272,815001,789,000971,00089,00010,76896,5041,788,00000000000000
       Accounts payable 
255,000
208,000
270,000
313,000
386,000
422,000
630,000
531,000
764,000
745,000
1,044,000
976,000
1,122,000
1,189,000
1,194,000
1,341,000
1,418,000
1,117,000
1,100,000
1,490,000
1,869,000
1,616,000
423,100
423,1001,616,0001,869,0001,490,0001,100,0001,117,0001,418,0001,341,0001,194,0001,189,0001,122,000976,0001,044,000745,000764,000531,000630,000422,000386,000313,000270,000208,000255,000
       Other Current Liabilities 
654,000
801,000
824,000
1,081,000
1,502,000
1,923,000
2,095,000
1,893,000
1,658,000
1,575,000
1,257,000
819,000
986,000
1,299,000
1,405,000
1,299,000
1,168,000
980,000
1,394,000
3,412,000
1,726,000
2,448,420
337,900
337,9002,448,4201,726,0003,412,0001,394,000980,0001,168,0001,299,0001,405,0001,299,000986,000819,0001,257,0001,575,0001,658,0001,893,0002,095,0001,923,0001,502,0001,081,000824,000801,000654,000
   > Long-term Liabilities 
2,942,000
2,009,000
2,019,000
2,073,000
2,634,000
2,810,000
2,563,000
2,518,000
2,249,000
2,661,000
2,925,000
2,841,000
3,205,000
2,898,000
3,352,000
2,529,000
2,734,000
4,222,000
5,105,000
6,888,000
6,792,000
6,778,000
2,931,300
2,931,3006,778,0006,792,0006,888,0005,105,0004,222,0002,734,0002,529,0003,352,0002,898,0003,205,0002,841,0002,925,0002,661,0002,249,0002,518,0002,563,0002,810,0002,634,0002,073,0002,019,0002,009,0002,942,000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
1,145,000
325,091
246,788
1,638,000
1,225,000
1,265,000
1,063,000
1,475,000
2,851,000
2,885,000
0
0
002,885,0002,851,0001,475,0001,063,0001,265,0001,225,0001,638,000246,788325,0911,145,00000000000000
> Total Stockholder Equity
4,062,000
4,113,000
3,828,000
3,761,000
3,359,000
3,657,000
4,465,000
5,831,000
7,824,000
8,809,000
9,555,000
11,054,000
11,269,000
11,580,000
11,732,000
11,254,000
11,425,000
11,468,000
11,233,000
11,827,000
13,837,000
13,978,000
11,176,000
11,176,00013,978,00013,837,00011,827,00011,233,00011,468,00011,425,00011,254,00011,732,00011,580,00011,269,00011,054,0009,555,0008,809,0007,824,0005,831,0004,465,0003,657,0003,359,0003,761,0003,828,0004,113,0004,062,000
   Common Stock
754,000
754,000
726,000
696,000
650,000
650,000
650,000
650,000
650,000
650,000
650,000
639,000
639,000
626,000
620,000
610,000
594,000
582,000
570,000
564,000
562,000
562,000
125,600
125,600562,000562,000564,000570,000582,000594,000610,000620,000626,000639,000639,000650,000650,000650,000650,000650,000650,000650,000696,000726,000754,000754,000
   Retained Earnings 
3,673,000
4,289,000
4,353,000
4,602,000
4,072,000
4,821,000
5,638,000
6,651,000
8,113,000
9,408,000
8,473,000
10,246,000
10,209,000
10,396,000
10,483,000
10,861,000
10,943,000
10,810,000
11,263,000
11,303,000
13,062,000
13,755,000
11,032,400
11,032,40013,755,00013,062,00011,303,00011,263,00010,810,00010,943,00010,861,00010,483,00010,396,00010,209,00010,246,0008,473,0009,408,0008,113,0006,651,0005,638,0004,821,0004,072,0004,602,0004,353,0004,289,0003,673,000
   Capital Surplus 00000000000000000000000
   Treasury Stock00000000000000000000000
   Other Stockholders Equity 
-365,000
-930,000
-1,391,000
-1,537,000
-1,363,000
-1,814,000
-1,823,000
-1,470,000
-939,000
465,000
432,000
169,000
421,000
558,000
629,000
-434,000
-224,000
76,000
-1,200,000
-80,000
213,000
-45,533
18,000
18,000-45,533213,000-80,000-1,200,00076,000-224,000-434,000629,000558,000421,000169,000432,000465,000-939,000-1,470,000-1,823,000-1,814,000-1,363,000-1,537,000-1,391,000-930,000-365,000



6.3. Balance Sheets

Currency in EUR. All numbers in thousands.




6.4. Cash Flows

Currency in EUR. All numbers in thousands.




6.5. Income Statements

Currency in EUR. All numbers in thousands.


6.6. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in EUR. All numbers in thousands.

Gross Profit (+$)
totalRevenue3,833,500
Cost of Revenue-2,024,000
Gross Profit1,809,5001,809,500
 
Operating Income (+$)
Gross Profit1,809,500
Operating Expense-1,150,500
Operating Income659,000659,000
 
Operating Expense (+$)
Research Development413,200
Selling General Administrative214,600
Selling And Marketing Expenses550,900
Operating Expense1,150,5001,178,700
 
Net Interest Income (+$)
Interest Income-
Interest Expense--
Other Finance Cost-80,400
Net Interest Income-80,400
 
Pretax Income (+$)
Operating Income659,000
Net Interest Income-80,400
Other Non-Operating Income Expenses-
Income Before Tax (EBT)417,100900,900
EBIT - interestExpense = 0
417,100
305,800
Interest Expense-
Earnings Before Interest and Taxes (EBIT)-417,100
Earnings Before Interest and Taxes (EBITDA)659,000
 
After tax Income (+$)
Income Before Tax417,100
Tax Provision-111,300
Net Income From Continuing Ops305,800305,800
Net Income305,800
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses3,174,500
Total Other Income/Expenses Net-241,90080,400
 

Technical Analysis of Novozymes AS
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Novozymes AS. The general trend of Novozymes AS is BULLISH with 71.4% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Novozymes AS's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (71.4%) Bearish trend (-71.4%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Novozymes AS Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Novozymes AS.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 75.99.

The bearish price targets are: 68.24 > 64.90 > 62.86.

Know someone who trades $NVZMY? Share this with them.👇

Novozymes AS Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Novozymes AS. The current mas is .

The long score for the Moving Averages is 12/14.
The longshort score for the Moving Averages is 10/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Novozymes AS Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Novozymes AS. The current macd is 0.29207332.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Novozymes AS price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Novozymes AS. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Novozymes AS price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Novozymes AS Daily Moving Average Convergence/Divergence (MACD) ChartNovozymes AS Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Novozymes AS. The current adx is 13.39.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -1/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Novozymes AS shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Novozymes AS Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Novozymes AS. The current sar is 72.62.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Novozymes AS Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Novozymes AS. The current rsi is 51.01. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 3/13.
The longshort score for the Relative Strength Index (RSI) is 2/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending down: The RSI is trending down. -1
Novozymes AS Daily Relative Strength Index (RSI) ChartNovozymes AS Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Novozymes AS. The current phase is Correction in bull market.

The long score for the Stochastic Oscillator is 2/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Novozymes AS price going up in the near term. +2
  • Trending down: The STOCH %K is trending down. -1
Novozymes AS Daily Stochastic Oscillator ChartNovozymes AS Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Novozymes AS. The current cci is -65.30437268.

Novozymes AS Daily Commodity Channel Index (CCI) ChartNovozymes AS Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Novozymes AS. The current cmo is -4.25875514.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Novozymes AS Daily Chande Momentum Oscillator (CMO) ChartNovozymes AS Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Novozymes AS. The current willr is -66.06606607.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Novozymes AS is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Novozymes AS Daily Williams %R ChartNovozymes AS Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Novozymes AS.

Novozymes AS Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Novozymes AS. The current atr is 1.48937365.

Novozymes AS Daily Average True Range (ATR) ChartNovozymes AS Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Novozymes AS. The current obv is 287,364.

Novozymes AS Daily On-Balance Volume (OBV) ChartNovozymes AS Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Novozymes AS. The current mfi is 33.36.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Novozymes AS Daily Money Flow Index (MFI) ChartNovozymes AS Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Novozymes AS.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-02-18DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-19SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-20MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-02-21STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-25DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-02-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-28WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-03-05RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2025-03-06STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-07CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-10SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-11CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-17STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-18MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-19MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-21DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-24CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-03-25STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-26STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-01STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-02STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-04-03MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-04STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-07MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-09STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-10MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-04-11DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-04-14SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-04-15STOCH LONG EXITThe %K line crosses below the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-04-16STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-17STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-21STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-04-22STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-24STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-04-28STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-04-29CCI LONG ENTRY SHORT CLOSE100 crossover to upside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-05-01STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-02STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-06SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-05-08SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-05-12DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-14MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-05-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-05-16WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-05-19STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-20WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-05-21STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-05-23RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-27STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-28RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-29STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-30CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-06-03MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-04MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-06-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-06MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-06-09STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-11STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-06-12BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-06-13STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-17SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-06-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-06-23DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-06-24DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-06-25DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-27STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-30STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-07-01STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-02STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-07-07STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-08WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-07-09MFI LONG ENTRY SHORT CLOSE20 crossover to upside

6.3. Candlestick Patterns

Novozymes AS Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Novozymes AS based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5051.009
Ma 20Greater thanMa 5072.814
Ma 50Greater thanMa 10070.296
Ma 100Greater thanMa 20064.734
OpenGreater thanClose71.290
Total4/5 (80.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Novozymes AS with someone you think should read this too:
  • Are you bullish or bearish on Novozymes AS? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Novozymes AS? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Novozymes AS

I send you an email if I find something interesting about Novozymes AS.


Comments

How you think about this?

Leave a comment

Stay informed about Novozymes AS.

Receive notifications about Novozymes AS in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.